10x Genomics, Inc.

TXG

Healthcare

$22.57+2.54%vs prev close

$7.72

$26.45

52W RangeNear 52W High

+0.92 (+4.22%)Past 1M

Price

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

9,787,416

Portfolio Weight

1.64%

in ETF 5.54%

Est. Value

$212M

30D Net

-$819K

Ray DalioBridgewater Associates

New Buy

177,734

Portfolio Weight

0.01%

Est. Value

$3M

Change

New position

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$24.00

vs Current ▲ +6.3% upside

Current$22.57

Low ~ High$17.00 ~ $32.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Canaccord Genuity

Buy

$32.00

+41.78%

$24.59

Maintain

2026-04-20

B of A Securities

Neutral

$30.00

+32.92%

$24.59

Maintain

2026-04-20

Barclays

Overweight

$30.00

+32.92%

$24.80

Maintain

2026-04-14

Citigroup

Neutral

$24.00

+6.34%

$21.82

Maintain

2026-04-07

William Blair

Outperform

N/A

$21.23

Upgrade

2026-03-31

1 / 1

Avg Target

$24.00

vs Current ▲ +6.3% upside

Buy

16 analysts

Strong Buy 1Buy 5Hold 10

Low $17.00

Current $22.57

High $32.00

Firm	Position	Target	Upside	Close	Action	Date
Canaccord Genuity	Buy	$32.00	+41.78%	$24.59	Maintain	26.04.20
B of A Securities	Neutral	$30.00	+32.92%	$24.59	Maintain	26.04.20
Barclays	Overweight	$30.00	+32.92%	$24.80	Maintain	26.04.14
Citigroup	Neutral	$24.00	+6.34%	$21.82	Maintain	26.04.07
William Blair	Outperform	N/A	N/A	$21.23	Upgrade	26.03.31

1 / 1

Price Information

Previous Close$22.01

Open$22.49

Day Range$21.88 - $23.15

52-Week Range$7.72 - $26.45

1-Year Change164.86%

Trading Volume

Volume1,963,713

Avg Volume (3mo)2,518,566

Valuation

Market Cap2.9B

Book Value$6.24

Shares Outstanding118,912,062

Financials

Revenue (TTM)642.8M

Net Income-43,544,000

EPS$-0.35

EBITDA-64,086,000

Profitability

P/E Ratio-

P/B Ratio3.62

Return on Equity (ROE)-5.78%

Return on Assets (ROA)-6.40%

Profit Margin-6.77%

EV/EBITDA-37.02

Beta2.05

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)39.21

Company Overview

10x Genomics is a life science technology company that provides instruments, consumables, and software for analyzing biological systems. Their main products include the Chromium platform for single-cell analysis and the Visium and Xenium platforms for spatial analysis of genes and proteins within tissues. They serve a global market of academic, government, and industry research institutions.

P/B

3.62

High valuation

ROE

-5.8%

Net loss

Beta

2.05

Extreme volatility

RSI(14)

39.2

Neutral zone

AI-generated summary. Not investment advice.